| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
|
Medicine details |
|
| Medicine name | empagliflozin (Jardiance®) |
| Formulation | 10 mg, 25 mg film-coated tablet |
| Reference number | 758 |
| Indication | Treatment of type 2 diabetes mellitus to improve glycaemic control in adults as add-on combination therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/06/2014 |
| NICE guidance | TA336: Empagliflozin in combination therapy for treating type 2 diabetes |